Jenna Payesko

Findings could lead to the development of an approach allowing for a safe, lifelong immunity to HIV.

Findings indicated that Macrilen stimulated the pituitary gland to produce the growth hormone more effectively than the ITT.

This is the first gene therapy approved in the US targeting mutations in a specific gene.

FMT delivered by capsules were shown to be 96.2% effective, the same success rate as delivered by colonoscopy.

The first-of-its-kind prescription digital medicine video game plans for regulatory filing in the first half of 2018.

New initiative encourages communities to implement proactive solutions.

Nearly half of the study participants achieved complete skin at week 16, while 87% maintained the response at week 52.

The study in Uganda suggests the global effort to eradicate HIV in high-risk populations is working.

The smart strap is the first medical accessory for a smartwatch to receive FDA approval.

While the abuse level has leveled off, overdose deaths continue to climb.

Greater reductions in brain glycolysis demonstrated a relationship to symptoms of Alzheimer’s disease like memory problems.

It sheds light on greater education needs about a gynecologic infection that impacts 1 in 3 women.

The committee warns against the approval due to inconsistent data, concerns about drug resistance and lack of endpoints met.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A study shows CRA presence has a negative correlation with the volume of SRF.

Two phase 3 clinical trials begin enrollment for treatment of manic episodes associated with bipolar I disorder.

If approved, this will be the first monthly injectable buprenorphine treatment for opioid use disorder.

Positive results showed 6 weeks of treatment associated with significant improvement of depressive symptoms in children and adolescents.

Rivaroxaban is the only Factor Xa inhibitor demonstrating superior efficacy in reducing recurrent VTE after initial treatment.

An arbovirologist discusses what animal models tell us about the sexual transmission of Zika virus.

It’s imperative healthcare providers strive to have a conversation with patients when prescribing medication.

FDA sends response letter for deficiencies found in Antares Pharma’s QuickShot Testosterone auto injector.

Evening-dosed psychostimulant is the first long-acting MPH single-dose formulation to show improvements in at-home early morning functional impairment.

The UN and WHO aim to reduce the burden of cholera globally by 90% reduction in deaths by 2030.

Learn more about the decrease in yellow fever vaccine production that will last until mid-2018.

Why is delafloxacin unique compared to other fluoroquinolones? Find out more.

Rochelle Walensky, MD, MPH, Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, discusses the future for HIV drug prices.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about challenges of Hepatitis C treatment.

Brianna Norton, DO, MPH, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, talks about the hottest topic in infectious disease.